Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: May 22, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
153
2012 to 2026
Breakthrough
74
Accelerated
153
Priority review
131
Orphan
121
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2012 | 7 | 1 |
| 2013 | 4 | 0 |
| 2014 | 6 | 3 |
| 2015 | 7 | 2 |
| 2016 | 5 | 2 |
| 2017 | 5 | 5 |
| 2018 | 8 | 1 |
| 2019 | 7 | 3 |
| 2020 | 13 | 7 |
| 2021 | 11 | 6 |
| 2022 | 5 | 4 |
| 2023 | 6 | 6 |
| 2024 | 7 | 4 |
| 2025 | 8 | 5 |
| 2026 | 2 | 3 |
153 approvals
Newest first. Hover a badge for what it means.
- Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
- Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
- Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
- Yuviwel (Navepegritide) · AscendisFeb 27, 2026
To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses
- Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
- Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTDNov 25, 2025Original approval · BLA 761434NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression
- Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp DohmeSep 19, 2025
To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab
- Forzinity (Elamipretide Hydrochloride) · Stealth BiotherapsSep 19, 2025
To improve muscle strength in patients with Barth syndrome weighing at least 30 kg
- Hernexeos (Zongertinib) · Boehringer IngelheimAug 8, 2025Original approval · NDA 219042NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy
- Modeyso (Dordaviprone Hydrochloride) · ChimerixAug 6, 2025
To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
- Lynozyfic (Linvoseltamab-Gcpt) · Rengeneron Pharmaceuticals, Inc.Jul 2, 2025
To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody
- Zegfrovy (Sunvozertinib) · DizalJul 2, 2025Original approval · NDA 219839NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy
- Datroway (Datopotamab Deruxtecan-Dlnk) · Daiichi Sankyo INCJun 23, 2025Original approval · BLA 761464NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
- Brukinsa (Zanubrutinib) · Beone Medicines USAJun 10, 2025
- Emrelis (Telisotuzumab Vedotin-Tllv) · Abbvie INCMay 14, 2025Original approval · BLA 761384NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy
- Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INCMay 8, 2025Original approval · NDA 219616NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy
- Vanrafia (Atrasentan Hydrochloride) · NovartisApr 2, 2025
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
- Opdivo Qvantig (Nivolumab, Hyaluronidase-Nvhy) · Bristol-Myers SquibbDec 27, 2024
- Bizengri (Zenocutuzumab-Zbco) · Merus N.V.Dec 4, 2024Original approval · BLA 761352NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat non-small cell lung cancer and pancreatic adenocarcinoma
- Ziihera (Zanidatamab-Hrii) · Jazz PharmsNov 20, 2024Original approval · BLA 761416NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer
- Livdelzi (Seladelpar Lysine) · Gilead Sciences INCAug 14, 2024Original approval · NDA 217899NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat primary biliary cholangitis (PBC)
- Krazati (Adagrasib) · BristolJun 21, 2024Efficacy supplement 5 · NDA 216340Breakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
- Iqirvo (Elafibranor) · IpsenJun 10, 2024Original approval · NDA 218860NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat primary biliary cholangitis in combination with ursodeoxycholic acid
- Retevmo (Selpercatinib) · Eli Lilly and COMay 29, 2024
- Imdelltra (Tarlatamab-Dlle) · Amgen INCMay 16, 2024Original approval · BLA 761344NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat extensive stage small cell lung cancer
- Ojemda (Tovorafenib) · Day One BiopharmsApr 23, 2024
- Ojemda (Tovorafenib) · Day One BiopharmsApr 23, 2024
To treat relapsed or refractory pediatric low-grade glioma
- Rezdiffra (Resmetirom) · MadrigalMar 14, 2024Original approval · NDA 217785NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
- Fabhalta (Iptacopan Hydrochloride) · NovartisDec 5, 2023Original approval · NDA 218276NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat paroxysmal nocturnal hemoglobinuria
- Augtyro (Repotrectinib) · BristolNov 15, 2023
To treat ROS1-positive non-small cell lung cancer
- Rozlytrek (Entrectinib) · Genentech INCOct 20, 2023
- Elrexfio (Elranatamab) · Pfizer INCAug 14, 2023Original approval · BLA 761345NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy
- Talvey (Talquetamab-Tgvs) · Janssen BiotechAug 9, 2023Original approval · BLA 761342NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies
- Columvi (Glofitamab-Gxbm) · Genentech INCJun 15, 2023
To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy
- Epkinly (Epcoritamab-Bysp) · Genmab US, Inc.May 19, 2023
To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy
- Qalsody (Tofersen) · Biogen MaApr 25, 2023
To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation
- Zynyz (Retifanlimab-Dlwr) · Incyte CorpMar 22, 2023
To treat metastatic or recurrent locally advanced Merkel cell carcinoma
- Filspari (Sparsentan) · TravereFeb 17, 2023
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
- Jaypirca (Pirtobrutinib) · Loxo OncolJan 27, 2023
To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor
- Leqembi (Lecanemab-Irmb) · Eisai INCJan 6, 2023Original approval · BLA 761269NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat Alzheimer's disease
- Lunsumio Velo (Mosunetuzumab-Axgb) · Genentech INCDec 22, 2022Original approval · BLA 761263NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma
- Krazati (Adagrasib) · BristolDec 12, 2022
To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy
- Tzield (Teplizumab-Mzwv) · Provention Bio INCNov 17, 2022Original approval · BLA 761183NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
- Elahere (Mirvetuximab Soravtansine-Gynx) · Immunogen INCNov 14, 2022
To treat patients with recurrent ovarian cancer that is resistant to platinum therapy
- Tecvayli (Teclistamab-Cqyv) · Janssen BiotechOct 25, 2022Original approval · BLA 761291NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy
- Lytgobi (Futibatinib) · Taiho OncologySep 30, 2022Original approval · NDA 214801NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
- Calquence (Acalabrutinib Maleate) · AstrazenecaAug 3, 2022Original approval · NDA 216387Accelerated approvalOrphan
- Vijoice (Alpelisib) · NovartisApr 5, 2022Original approval · NDA 215039NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
- Vonjo (Pacritinib Citrate) · SobiFeb 28, 2022
To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.